Published in TB and Outbreaks Week, January 7th, 2003
Adequate supplies of injectable flu vaccine are now available in the U.S. as a result of recent capacity increases provided by other manufacturers.
In addition, Wyeth has chosen to pursue new flu immunization technologies - specifically through its partnership with MedImmune to develop and market FluMist, an intranasal influenza vaccine. The focus on developing new vaccine products should result in better choices for physicians and patients, but requires a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week